Mitochondrial dysfunction is associated with various chronic diseases and cancers, including neurodegenerative diseases and ...
New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseasesHAIFA, Israel, Jan. 13, 2026 ...
New Review Integrates Human, Animal, and Cellular Evidence to Reframe AD as a Triad-Centered Disorder Alzheimer’s disease (AD ...
Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.
NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...
Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made a huge breakthrough, proving for the first time how mitochondrial ...
Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will present ...
Despite being renowned as the “powerhouse of the cell,” mitochondria can also be a source of heartache for those living with mitochondrial disease—especially when planning to have children. Because ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback